Sandoz is focused on therapies for Cardiovascular, CNS, Dermatology, Gastrointestinal & Hormonal disorders, Metabolism, Oncology, Ophthalmic pain, and Respiratory disorders. Richard has also built and led successful teams and organizations with a strong focus on inclusive culture and developing talent. EPS was USD 0.81 (-5%, +5% cc) in line with net income. Novartis continues to expect the previously-announced divestment of the Sandoz US oral solids and dermatology portfolio to be completed during 2019, pending closing conditions including regulatory approvals. According to this study, over the next five years the Donepezil market will register a -1.6% CAGR in terms of revenue, the global market size will reach US$ 830 million by 2024, from US$ 920 million in 2019. Free cash flow was €6.1 billion in 2019, up from €5.4 billion in the prior year. [4]  Removes Alcon and the Sandoz US dermatology and oral solids portfolio from both 2019 and 2018. 2019 Proxy Statement (PDF 1.98 MB) PDF Format Download (opens in new window) 2018 Annual Report (PDF 1.63 MB) PDF Format Download (opens in new window) 2016 . If mid-April exchange rates prevail for the remainder of 2019, the currency impact for the year would be negative 3 percentage points on net sales and negative 3 to 4 percentage points on core operating income. Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. You should not place undue reliance on these statements. Novartis remains fully committed to this business until it is divested to Aurobindo. • La législation canadienne en matière d’impôt sur le revenu permet à un contribuable de différer l’impôt sur le dividende en nature si un choix est produit. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "guidance," "transformation," "continued," "potential", "launches," "on track" "launched," "filed," "launch," "expected," "to grow," "will," "enter," "pipeline," "commitment," "well positioned," "future," "strategy," "priorities," "embrace," "deliver," "go big," "build," "allows," "expect," "to be completed,"  "closing conditions," "committed," "continued," "growth drivers," "Priority Review Voucher," "submissions," "filings," "to be presented," "potentially," "if approved," "aims," "outlook," "unforeseen," "forecast," "may," "would," "continues," "aiming," "vision," "priority review," "PRIME designation," "Sakigake designation," "enrollment," "planned," "upcoming," "Fast Track designation," "Orphan designation," "scheduled," or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products; or regarding the potential outcome, or financial or other impact on Novartis, of the spinoff of our Alcon Division, or of the proposed divestiture of certain portions of our Sandoz Division business in the US; or regarding the potential impact of the share buyback plan; or regarding potential future sales or earnings of the Group or any of its divisions or potential shareholder returns; or by discussions of strategy, plans, expectations or intentions. The total number of shares outstanding increased by 11.6 million versus December 31, 2018. See page 32 of the Condensed Interim Financial Report for a full explanation. 2018. Global sales of Biopharmaceuticals grew 11% (cc) driven by Europe with continued strong double-digit growth from Rixathon (rituximab), Hyrimoz (adalimumab) and Erelzi (etanercept). In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in this release; the potential that the strategic benefits, synergies or opportunities expected from the Alcon and Sandoz transactions may not be realized or may be more difficult or take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and will continue this year; safety, quality or manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential litigation with respect to the proposed transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally; uncertainties involved in the development or adoption of potentially transformational technologies and business models; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis aims to offset the dilutive impact from equity based participation plans of associates over the remainder of the year. The Sandoz pocket book provides a comprehensive overview of our company, our business areas, corporate responsibility work and information about Sandoz as an employer of choice. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. In order to comply with International Financial Reporting Standards (IFRS), Novartis has separated the Group's reported financial data for the current and prior years into "continuing" and "discontinued" operations. 339 kb EN Invitation Full-Year 2019 Results. English (PDF 4.0 MB) Novartis Pipeline. In 2019, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to just over 47 billion U.S. dollars. « Sandoz se consacre à accroître son portfolio de biosimilaires au Canada et Hyrimoz ... mènent à une substitution non médicale obligatoire et qui auraient été introduites dans toutes les provinces en 2019 (étanercept et infliximab seulement) pourraient générer 239,6 M$ en économies nationales. Also in Q1 2019, Novartis repaid the USD 3.0 billion, 5.125% coupon bond issued in February 2009 at maturity. Sales of Enbrel in Q2/19 were $1.363 billion worldwide, representing 24.45% of the firms product revenues and its largest individual patented drug by revenue. Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines. Readers should not rely upon the information in these pages as current or accurate after their publication dates. 2019 à 19 ... elles représentent un complément de revenu pour le trentenaire. Core operating income guidance revised upwards: expected to grow high single digit (cc). In the same quarter, 13.8 million shares (for an equity value of USD 0.5 billion) were delivered as a result of options exercised and share deliveries related to participation plans of associates. * Third Sandoz biosimilar approved in … English (PDF 8.0 MB) | Deutsch (PDF 8.0 MB). La Belgique est l'un des nombreux pays à bénéficier de ce don. Please find full media release in English attached and on the following link:http://hugin.info/134323/R/2242311/884922.pdf. At the beginning of 2019, ... Sandoz Targets 40 First-To-File Opportunities In The US. Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. The results of the Alcon business are reported as discontinued operations. L’inflammation et les problèmes respiratoires … Our strategy is to focus Novartis as a leading medicines company with five priorities: embrace operational excellence, deliver transformative innovation, go big on data science, build trust with society, and build a new culture by unleashing the power of our people. TOP 10 PHARMACEUTICAL COMPANIES BY REVENUES: JOHNSON AND JOHNSON: $82.1 billion ROCHE: $63.3 billion PFIZER: $51.75 billion NOVARTIS: $47.45 billion MERCK: $46.84 billion GSK: $ 43.92 billion SANOFI: $39.28 billion ABBVIE: $33.27 billion ABBOTT: $31.90 billion TAKEDA: 31.17 billion Other major pharma companies are: BMS In addition, Richard oversees the commercial digital platforms across all of GSK's pharmaceutical franchises. This presentation remains on the Novartis website for historical purposes only. We enter an exciting period with expected launches of Zolgensma, BYL719 and brolucizumab and multiple late stage readouts. 2019 Outlook . Net sales were USD 11.1 billion (+2%, +7% cc) in the first quarter driven by volume growth of 11 percentage points (cc), mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. This exclusive certification for exceptional employee offerings highlights the company’s commitment to build an attractive and rewarding workplace for its employees, with a high-energy and agile culture. New focused medicines company guidance Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019. 10.2.2 Sandoz Description, Business Overview and Total Revenue 10.2.3 Sandoz Megestrol Sales, Revenue and Gross Margin (2015-2020) 10.2.5 Sandoz Recent Development Richard is a Pharmacist by training and started his pharma business career as a sales representative at G.D. Searle in the U.K. Underpinning our financial results in the first quarter is a continued focus on key growth drivers including: Net sales of the top 20 Innovative Medicines products in Q1, Strengthen R&D - Key developments from the first quarter, Results from ongoing trials and other highlights. Revenue Annual and half yearly information News & announcement Next. Core net income was USD 2.8 billion (+5%, +13% cc) as growth in core operating income was partly offset by the discontinuation of core income from the GSK consumer healthcare joint venture. Notre mission au sein du groupe Novartis est de mettre à la disposition du plus grand nombre des médicaments de qualité à un prix plus abordable. The results of this business are included in continuing operations until the time of the divestment. Core EPS was USD 1.21 (+5%, +13% cc) in line with core net income. Find out more at www.novartis.com. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Core operating income amounted to USD 350 million for discontinued operations (-3%, +7% cc) as higher sales and gross margin, as well as discontinuation of depreciation and software amortization from March 1 (USD 30 million) were partly offset by growth investments. Sandoz net sales were USD 2.3 billion (-8%, -2% cc) in the first quarter as 9 percentage points (cc) of price erosion mainly in the US, were partially offset by volume growth of 7 percentage points (cc). The information in the presentation on this page was factually accurate on the date of publication. 2020 Proxy Statement (PDF 3.42 MB) PDF Format Download (opens in new window) 2019 Annual Report (PDF 1.09 MB) PDF Format Download (opens in new window) 2017. The Corporate Fact Sheets provide a comprehensive overview of Novartis overall as well as our divisions (Innovative Medicines, Sandoz), our research organization NIBR, and outline our commitment to associates as well as Corporate Responsibility. Download the media releaseEnglish (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB), Watch the media webcast 09:30 CET - 08:30 GMT - 03:30 EST, Download the media presentation (PDF 1.2 MB), Watch the investor webcast14:00 CET - 13:00 GMT - 08:00 EST, Download the investor presentation (PDF 3.6 MB). Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other As of March 31, 2019, the net debt increased by USD 5.3 billion to USD 21.5 billion versus December 31, 2018. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. 2019. Free cash flow for the total Group amounted to USD 1.8 billion. Results for discontinued operations in the first quarter of 2019 include a full quarter of results from the Alcon Division and certain Corporate costs directly attributable to Alcon. Forecast assumption that no Gilenya generics enter in 2019; however, generic competitors may still launch at risk. The increase was mainly driven by the USD 6.6 billion annual dividend payment, partly offset by USD 1.9 billion free cash flow from continuing operations in Q1 2019. Operating income was USD 2.2 billion (-5%, +4% cc) driven by higher Innovative Medicines sales and improved gross margin, partly offset by growth investments, a net impairment charge and lower divestment gains. Core operating income margin in constant currencies increased by 2.6 percentage points; currency had a negative impact of 0.6 percentage points, resulting in a net increase of 2.0 percentage points to 29.3% of net sales. 2019 – delivering on our strategy, producing strong finan - cial results, and making a significant impact on society by improving and extending the lives of people across the globe. Novartis Institutes for BioMedical Research, 2019 Q4 and Full Year Results Presentation & Transcript. Balance sheet impacts of the Alcon spin off will be included in the second quarter results. 2019 revenue: $47.45 billion 2018 revenue: $44.75 billion Headquarters: Basel, Switzerland. 1.30.2020. An explanation of non-IFRS measures can be found on page 41 of the Condensed Interim Financial Report. Volume contributed 12 percentage points (cc) to sales growth. The Brand Rankings, Top 50 Global Pharma Companies - 2019 by Pharmaceutical Executive Top 50 Global Pharma Companies - 2019 (Pharmaceutical Executive) | Ranking The Brands select Unless otherwise noted, all growth rates in this Release refer to same period in prior year. New focused medicines company guidance Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019. Pricing had a negative impact of 1 percentage point (cc). In 2019, Sandoz has generated revenue of $9.73B from its generic segment. [3]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. * Hyrimoz® approved for use in all same indications as reference medicine* including rheumatology, gastroenterology and dermatology. Apotex Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. As part of the strategy to focus Novartis, the Alcon business was spun-off as a separate public company on April 9, following the shareholder vote on February 28. En complément de notre communication en date du 20 décembre 2019 et du 9 janvier 2020, nous vous informons que les spécialités Amoxicilline SANDOZ 1 g, comprimé dispersible (boîtes de 6 et de 14 comprimés) contenant la notice actualisée sont désormais disponibles. PDF document. In April, we took an important step with the spin-off of our former Alcon eye care devices division, further trans - forming Novartis into a focused medicines company. Analysts expect Novartis’s revenues to see YoY changes of -3.86% to $49.90 billion in 2019, 3.89% to $51.84 billion in 2020, and 5.08% to $54.47 billion in 2021. For the total Group, net income amounted to USD 1.8 billion compared to USD 2.0 billion in the prior year, and basic earnings per share decreased to USD 0.77 from USD 0.87. A replay will be available after the live webcast by visiting.https://www.novartis.com/investors/event-calendar, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. Basel, April 24, 2019 - Commenting on the results, Vas Narasimhan, CEO of Novartis, said: "Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off, and strong operational execution leading us to revise 2019 profit guidance upwards. From a divisional perspective, we expect net sales performance (cc) in 2019 to be as follows: Boston, January 7, 2019 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). Lannett Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at.https://www.novartis.com/investors/event-calendar. The spin-off allows shareholders to benefit from a standalone Alcon and a Novartis with capital and management attention fully focused on medicines. With our strong pipeline, focus on productivity, and commitment to cultural transformation, we are well positioned for growth in 2019 and the future.". Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. In 2019, Novartis AG made approximately 38.5 billion U.S. dollars from its pharmaceuticals business segment. Torrent Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2019. As Narasimhan outlined, Novartis’ key strategic goals for Sandoz include achieving a profile that delivers low-to-mid single digit revenue growth; with core margins and core returns on sales in the mid-to-high 20s. As of Q1 2019, the long-term credit rating for the company is A1 with Moody's Investors Service and AA- with S&P Global Ratings. We also provide information on discontinued operations. See page 32 of the Condensed Interim Financial Report for full explanation, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below:http://hugin.info/134323/R/2242311/884910.pdf. English (PDF 6 MB) Making Access Happen - The Sandoz Magazine Story-based approach to discussing the challenges many people around the world have accessing healthcare, possible solutions to the various problems … Net sales in 2019 are expected to grow mid-single digit (cc). About 105,000 people of more than 140 nationalities work at Novartis around the world. Core operating income was USD 3.3 billion (+9%, +18% cc) mainly driven by higher Innovative Medicines sales and improved gross margin, partly offset by growth and launch investments, including for Zolgensma. … Regulated information Regulated information ... 2019: Strong results and a successful transformation. [5]  Discontinued operations described on page 32 of the Condensed Interim Financial Report. The increase was driven by higher underlying operating profit and a €0.8 billion improvement in changes in working capital, where the prior year was impacted by the disposal of our spreads business. Renseignements : Paule Pelletier Sandoz Canada Inc. +1 514 702-7699 paule.pelletier@sandoz.com / communications.canada@sandoz.com Ces communiqués peuvent vous intéresser aussi 31 déc 2020 The previously announced share buyback of up-to USD 5 billion in June 2018 is expected to be completed in 2019. Par Philippine KAUFFMANN - 15 juil. Novartis has appointed Richard Saynor as CEO of Sandoz effective no later than August 1, 2019. Sandoz fait don d’hydroxychloroquine à la Belgique. Barring unforeseen events . Novartis assumes no responsibility to update the information to reflect subsequent developments. [1]  Constant currencies (cc), core results and free cash flow are non-IFRS measures. Prior to GSK, Richard held Commercial Operations leadership roles at Sandoz and oversaw a strong expansion of Sandoz' generics business across Asia, Latin America and Turkey.